IMJUDO tremelimumab 300 mg/ 15 mL concentrated injection vial

מדינה: אוסטרליה

שפה: אנגלית

מקור: Department of Health (Therapeutic Goods Administration)

מרכיב פעיל:

tremelimumab, Quantity: 300 mg

זמין מ:

AstraZeneca Pty Ltd

טופס פרצבטיות:

Injection, concentrated

הרכב:

Excipient Ingredients: histidine hydrochloride monohydrate; disodium edetate; polysorbate 80; water for injections; trehalose dihydrate; histidine

מסלול נתינה (של תרופות):

Intravenous Infusion

יחידות באריזה:

1 vial

סוג מרשם:

(S4) Prescription Only Medicine

סממני תרפויטית:

Hepatocellular Carcinoma (HCC),IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.

leaflet_short:

Visual Identification: Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 48 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

מצב אישור:

Registered

תאריך אישור:

2023-06-23